Wall Street brokerages expect Synnex (NYSE:SNX) to post $4.68 billion in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Synnex’s earnings, with the lowest sales estimate coming in at $4.66 billion and the highest estimate coming in at $4.70 billion. Synnex reported sales of $3.94 billion during the same quarter last year, which indicates a positive year over year growth rate of 18.8%. The firm is expected to report its next earnings results on Thursday, June 28th.
According to Zacks, analysts expect that Synnex will report full year sales of $19.45 billion for the current fiscal year, with estimates ranging from $19.36 billion to $19.55 billion. For the next year, analysts expect that the company will post sales of $20.22 billion per share, with estimates ranging from $19.83 billion to $20.46 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Synnex.
Top Growth Stocks To Buy Right Now: PIMCO California Municipal Income Fund III(PZC)
Advisors' Opinion:- [By Ethan Ryder]
Headlines about Pimco CA Muni. Income Fund III (NYSE:PZC) have trended somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pimco CA Muni. Income Fund III earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the investment management company an impact score of 48.0089575306336 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
- [By Max Byerly]
PZ Cussons (LON:PZC) had its price objective decreased by Numis Securities from GBX 255 ($3.40) to GBX 230 ($3.06) in a research note issued to investors on Thursday. Numis Securities currently has a hold rating on the stock.
Top Growth Stocks To Buy Right Now: SPDR S&P Biotech ETF (XBI)
Advisors' Opinion:- [By Jim Crumly]
Tech stocks were strong today, but biotech really took off on merger and acquisition news; the�SPDR S&P Biotech ETF (NYSEMKT:XBI) jumped 2.7%.�
- [By Jim Crumly]
Industrials led the market, with the�Industrial Select SPDR ETF (NYSEMKT:XLI) rising 1.5%. Biotechnology stocks struggled; the�SPDR S&P Biotech ETF (NYSEMKT:XBI) fell 2%.
- [By ]
Remember the SPDR S&P Biotech ETF (NYSE:XBI) chart I showed you Friday? Take a look at this ETF bouncing off its 50-day moving average one more time:
- [By ]
In a sea of red, small-cap biotech stocks stood strong during Wednesday��s trading session. The SPDR S&P Biotech ETF (NYSE:XBI) finished the day higher by more than 1.25% while the Nasdaq Composite was stuck in the red. XBI��s comeback rally that began to materialize just before Christmas is now threatening to break out to new highs.
- [By Jim Crumly]
Biotech stocks notched big gains for the second straight day, with the�SPDR S&P Biotech ETF (NYSEMKT:XBI)�adding 2.3%. Retail stocks also were strong; the�SPDR S&P Retail ETF (NYSEMKT:XRT) closed up 1%.
Top Growth Stocks To Buy Right Now: HSBC Holdings PLC (HSBA)
Advisors' Opinion:- [By Ethan Ryder]
HSBC (LON:HSBA) had its price target dropped by equities research analysts at Citigroup from GBX 810 ($10.78) to GBX 800 ($10.65) in a report released on Tuesday. The brokerage currently has a “buy” rating on the financial services provider’s stock. Citigroup’s price target points to a potential upside of 9.59% from the stock’s previous close.
- [By Joseph Griffin]
HSBC (LON:HSBA) had its target price lowered by equities research analysts at Shore Capital from GBX 721 ($9.60) to GBX 625 ($8.32) in a report issued on Tuesday. The brokerage presently has a “sell” rating on the financial services provider’s stock. Shore Capital’s price objective indicates a potential downside of 14.71% from the company’s previous close.
No comments:
Post a Comment